GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Operating Margin %

Audeo Oncology (Audeo Oncology) Operating Margin % : -7,883.61% (As of Sep. 2012)


View and export this data going back to . Start your Free Trial

What is Audeo Oncology Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Audeo Oncology's Operating Income for the three months ended in Sep. 2012 was $-4.81 Mil. Audeo Oncology's Revenue for the three months ended in Sep. 2012 was $0.06 Mil. Therefore, Audeo Oncology's Operating Margin % for the quarter that ended in Sep. 2012 was -7,883.61%.

The historical rank and industry rank for Audeo Oncology's Operating Margin % or its related term are showing as below:


AURX's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.075
* Ranked among companies with meaningful Operating Margin % only.

Audeo Oncology's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Audeo Oncology's Operating Income for the three months ended in Sep. 2012 was $-4.81 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2012 was $-9.18 Mil.


Audeo Oncology Operating Margin % Historical Data

The historical data trend for Audeo Oncology's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Operating Margin % Chart

Audeo Oncology Annual Data
Trend Jun10 Jun11 Jun12
Operating Margin %
- - -

Audeo Oncology Quarterly Data
Jun11 Mar12 Jun12 Sep12
Operating Margin % - - - -7,883.61

Competitive Comparison of Audeo Oncology's Operating Margin %

For the Drug Manufacturers - General subindustry, Audeo Oncology's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Audeo Oncology's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Operating Margin % falls into.



Audeo Oncology Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Audeo Oncology's Operating Margin % for the fiscal year that ended in Jun. 2012 is calculated as

Operating Margin %=Operating Income (A: Jun. 2012 ) / Revenue (A: Jun. 2012 )
=-9.481 / 0
= %

Audeo Oncology's Operating Margin % for the quarter that ended in Sep. 2012 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2012 ) / Revenue (Q: Sep. 2012 )
=-4.809 / 0.061
=-7,883.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Audeo Oncology  (DELISTED:AURX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Audeo Oncology Operating Margin % Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Audeo Oncology (Audeo Oncology) Business Description

Traded in Other Exchanges
N/A
Address
Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.